Philadelphia Chromosome Negative Myeloproliferative Neoplasms

Program Status

Open – We are accepting applications for new and renewal patients. If your application for assistance is approved you can begin receiving funding immediately.

Assistance Amount

$8,500 per year. Patients may apply for a second grant during their eligibility period subject to availability of funding.

Eligibility Criteria

1. The patient must be getting treatment for Philadelphia chromosome negative myeloproliferative neoplasms.
2. The patient must have health insurance that covers his or her qualifying medication or product. 
3. The patient’s medication or product must be listed on PAN’s list of covered medications.
4. The patient’s income must fall at or below 500% of the Federal Poverty Level.
5. The patient must reside and receive treatment in the United States or U.S. territories. (U.S. citizenship is not a requirement.)

Diagnosis Codes:

ICD-10: C92.20, C92.21, C92.22, C94.40, C94.41, C94.42, D45, D47.1, D47.3, D47.4, D75.81

About the Disease:

Philadelphia chromosome negative myeloproliferative neoplasms (MPN) is a cancer associated with increased production of blood cells. It affects the circulatory system. Subtypes include polycythemia vera, essential thrombocythemia, myelofibrosis, chronic neutrophilic leukemia, chronic eosinophilic leukemia, and chronic myeloid leukemia BCR/ABL Negative.

Source: National Institutes of Health